Residual cancer lymphocytes in patients with chronic
lymphocytic leukemia after therapy show increased expression of
surface antigen CD52 detected using quantitative fluorescence
cytometry

J 2014

Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry

PEVNÁ, Michaela; Michael DOUBEK; Petr ČOUPEK; Olga STEHLÍKOVÁ; Martin KLABUSAY et al.

Základní údaje

Originální název

Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry

Autoři

PEVNÁ, Michaela; Michael DOUBEK; Petr ČOUPEK; Olga STEHLÍKOVÁ a Martin KLABUSAY

Vydání

Clinical Lymphoma, Myeloma and Leukemia, 2014, 2152-2650

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.020

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.clml.2014.06.006

UT WoS

000342879300009

Klíčová slova anglicky

CD20, Remission, Residual Disease, Small lymphocytic lymphoma, Surface CD20

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 1. 2015 11:50, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The quantitative determination of the expression of CD20 and CD52 antigens in chronic lymphocytic leukemia (CLL) is important for treatment with monoclonal antibodies (mAbs). Patients with CLL in complete or partial remission have a higher level of CD52 antigen expression compared with patients with CLL untreated, in progression, or diagnosed with small lymphocytic lymphoma (SLL). Our results support the possible signifi- cance of alemtuzumab consolidation. Background: Rituximab and alemtuzumab, mAbs used in recent years to treat CLL, are directed against antigens CD20 and CD52. CD20 is not highly expressed by CLL tumor cells, and rituximab does not have significant effectiveness in CLL unless combined with chemotherapy. Alemtuzumab targets CD52, which is much more highly expressed, and is currently the most effective agent used alone for CLL. Variability in expression of both antigens among these patients might be related to different individual therapeutic responses to mAb therapy. Patients and Methods: A total 95 patients diagnosed with CLL and/or SLL were divided into 4 groups: (1) untreated; (2) in complete or partial remission; (3) disease in progression; and (4) diagnosed with SLL. Flow cytometry of peripheral blood cells included gating of the CD5þCD19þ tumor population, within which mean fluorescence intensity of fluorescein isothiocyanate (FITC) conjugated with anti-CD20 or anti-CD52 antibody was measured. The resulting expression of the 2 antigens was deduced from the calibration curve using Quantum FITC particles. Results: Expression of CD20 showed no significant differences among the 4 groups of patients. However, significantly greater expression of surface antigen CD52 was recorded in patient group 2 in complete or partial remission (P < .001). Conclusion: The residual population of CLL cells after therapy is characterized by increased surface detection of CD52. Although the exact cause of this phenomenon is unknown, our results provide a basis to consider the potential for CLL consolidation therapy using alemtuzumab.

Návaznosti

NS9670, projekt VaV

Název: Analýza intracelulárních Ca2+ signálů v patologii nádorových buněk leukemií a lymfomů, v regulaci nádorového růstu a indukci apoptózy v odpovědi na terapii monoklonálními protilátkami, detekovaných pomocí fotoproteinů a fluorescenčních indikátorů.

Investor: Ministerstvo zdravotnictví ČR, Analýza intracelulárních Ca2+ signálů v patologii nádorových buněk leukemií a lymfomů, v regulaci nádorového růstu a indukci apoptózy v odpovědi na terapii monoklonálními protilátkami, detekovaných pomocí fotoproteinů a fluorescenčních indikátorů

Citovat

PEVNÁ, Michaela; Michael DOUBEK; Petr ČOUPEK; Olga STEHLÍKOVÁ a Martin KLABUSAY. Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry. Clinical Lymphoma, Myeloma and Leukemia. 2014, roč. 14, č. 5, s. 411-418. ISSN 2152-2650. Dostupné z: https://doi.org/10.1016/j.clml.2014.06.006.

@article{1212665,
   author = {Pevná, Michaela and Doubek, Michael and Čoupek, Petr and Stehlíková, Olga and Klabusay, Martin},
   article_number = {5},
   doi = {https://doi.org/10.1016/j.clml.2014.06.006},
   keywords = {CD20, Remission, Residual Disease, Small lymphocytic lymphoma, Surface CD20},
   language = {eng},
   issn = {2152-2650},
   journal = {Clinical Lymphoma, Myeloma and Leukemia},
   note = {Evidenční list neuvádí žádného domácího autora pro MU.},
   title = {Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry},
   url = {http://ac.els-cdn.com/S2152265014001487/1-s2.0-S2152265014001487-main.pdf?_tid=842eb21c-8153-11e4-96cb-00000aacb35f&acdnat=1418315822_d98aebf34d5184e1c7afe9df1e5ceb93},
   volume = {14},
   year = {2014}
}

TY  - JOUR
ID  - 1212665
AU  - Pevná, Michaela - Doubek, Michael - Čoupek, Petr - Stehlíková, Olga - Klabusay, Martin
PY  - 2014
TI  - Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry
JF  - Clinical Lymphoma, Myeloma and Leukemia
VL  - 14
IS  - 5
SP  - 411-418
EP  - 411-418
SN  - 21522650
N1  - Evidenční list neuvádí žádného domácího autora pro MU.
KW  - CD20, Remission, Residual Disease, Small lymphocytic lymphoma, Surface CD20
UR  - http://ac.els-cdn.com/S2152265014001487/1-s2.0-S2152265014001487-main.pdf?_tid=842eb21c-8153-11e4-96cb-00000aacb35f&acdnat=1418315822_d98aebf34d5184e1c7afe9df1e5ceb93
N2  - The quantitative determination of the expression of CD20 and CD52 antigens in chronic lymphocytic leukemia (CLL) is important for treatment with monoclonal antibodies (mAbs). Patients with CLL in complete or partial remission have a higher level of CD52 antigen expression compared with patients with CLL untreated, in progression, or diagnosed with small lymphocytic lymphoma (SLL). Our results support the possible signifi- cance of alemtuzumab consolidation. Background: Rituximab and alemtuzumab, mAbs used in recent years to treat CLL, are directed against antigens CD20 and CD52. CD20 is not highly expressed by CLL tumor cells, and rituximab does not have significant effectiveness in CLL unless combined with chemotherapy. Alemtuzumab targets CD52, which is much more highly expressed, and is currently the most effective agent used alone for CLL. Variability in expression of both antigens among these patients might be related to different individual therapeutic responses to mAb therapy. Patients and Methods: A total 95 patients diagnosed with CLL and/or SLL were divided into 4 groups: (1) untreated; (2) in complete or partial remission; (3) disease in progression; and (4) diagnosed with SLL. Flow cytometry of peripheral blood cells included gating of the CD5þCD19þ tumor population, within which mean fluorescence intensity of fluorescein isothiocyanate (FITC) conjugated with anti-CD20 or anti-CD52 antibody was measured. The resulting expression of the 2 antigens was deduced from the calibration curve using Quantum FITC particles. Results: Expression of CD20 showed no significant differences among the 4 groups of patients. However, significantly greater expression of surface antigen CD52 was recorded in patient group 2 in complete or partial remission (P < .001). Conclusion: The residual population of CLL cells after therapy is characterized by increased surface detection of CD52. Although the exact cause of this phenomenon is unknown, our results provide a basis to consider the potential for CLL consolidation therapy using alemtuzumab.
ER  -

PEVNÁ, Michaela; Michael DOUBEK; Petr ČOUPEK; Olga STEHLÍKOVÁ a Martin KLABUSAY. Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry. \textit{Clinical Lymphoma, Myeloma and Leukemia}. 2014, roč.~14, č.~5, s.~411-418. ISSN~2152-2650. Dostupné z: https://doi.org/10.1016/j.clml.2014.06.006.

Přehled o publikaci